NuVasive's cervical interbody implant earns additional FDA indications

Spinal Tech

NuVasive's Modulus cervical interbody implant was approved by the FDA for use with a bone void filler, the devicemaker said Feb. 21.

The new indication makes the cervical implant compatible with Attrax Putty, NuVasive's synthetic bone graft substitute, according to a news release. The putty was first approved for thoracolumbar interbody fusion in December 2021.

"This clearance represents a significant milestone towards that goal, expanding our advanced materials combination of Modulus and Attrax Putty to our cervical interbody within the C360 portfolio," Ryan Donahoe, NuVasive's chief technology officer, said in the release.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers